Rajeshkumar N V, Kuttan R
Amala Cancer Research Centre, Thrissur, India.
Indian J Exp Biol. 2001 Jul;39(7):654-9.
Cancer chemopreventive potential of Cancare, a multi-herbal formulation on chemically induced tumours was studied by N-nitrosodiethylamine (NDEA) induced hepatocarcinogenesis in rats and 20-methylcholanthrene (20-MC) induced sarcoma development in mice. Oral administration of Cancare was found to inhibit the liver tumour development induced by N-nitrosodiethylamine. Animals administered with NDEA had visible liver tumours by the end of 30th weeks and the liver weight was raised to 6.1 +/- 1.4 g/ 100 g body wt. None of the animals treated with Cancare (150 mg/ kg) developed any visible liver tumours by this period and the liver weight was 3.0 +/- 0.6 g/ 100 g body wt. Gamma-Glutamyl transpeptidase, a marker of hepatocellularcarcinoma, which was raised to 83.7 +/- 8. 9 U/l in serum of NDEA treated group was reduced to 35.2 +/- 6.1 U/l by simultaneous administration of Cancare. Elevated levels of serum alkaline phosphatase, glutamate pyruvate transaminase, bilirubin, liver glutathione S-transferase, glutathione and gamma-Glutamyl transpeptidase in the NDEA administered group was significantly reduced by Cancare administration. Cancare administration inhibited the sarcoma development and increased the life span of mice administered with 20-MC dose dependently. All animals in the control group developed sarcomas by 150th day and dead by 174th day after 20-MC administration. Cancare administration (30 mg and 150 mg/kg) inhibited the sarcoma development (46.7 and 60%) as well as increased the life span (53.3 and 66.7%) as estimated on 240th day after 20-MC administration. The results are indicative of the chemopreventive potential of Cancare against chemically induced neoplasmas.
通过N-亚硝基二乙胺(NDEA)诱导大鼠肝癌发生以及20-甲基胆蒽(20-MC)诱导小鼠肉瘤发生,研究了一种多草药配方Cancare对化学诱导肿瘤的癌症化学预防潜力。发现口服Cancare可抑制N-亚硝基二乙胺诱导的肝脏肿瘤发展。给予NDEA的动物在第30周结束时出现可见的肝脏肿瘤,肝脏重量增加到6.1±1.4 g/100 g体重。在此期间,用Cancare(150 mg/kg)治疗的动物均未出现任何可见的肝脏肿瘤,肝脏重量为3.0±0.6 g/100 g体重。γ-谷氨酰转肽酶是肝细胞癌的标志物,在NDEA治疗组血清中升高至83.7±8.9 U/L,同时给予Cancare后降至35.2±6.1 U/L。给予Cancare可显著降低NDEA给药组血清碱性磷酸酶、谷氨酸丙酮酸转氨酶、胆红素、肝脏谷胱甘肽S-转移酶、谷胱甘肽和γ-谷氨酰转肽酶的升高水平。给予Cancare可剂量依赖性地抑制肉瘤发展并延长给予20-MC小鼠的寿命。对照组所有动物在给予20-MC后第150天出现肉瘤,并在第174天死亡。根据给予20-MC后第240天的估计,给予Cancare(30 mg和150 mg/kg)可抑制肉瘤发展(分别为46.7%和60%)并延长寿命(分别为53.3%和66.7%)。结果表明Cancare对化学诱导肿瘤具有化学预防潜力。